期刊
CLINICS IN CHEST MEDICINE
卷 28, 期 2, 页码 331-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2007.02.002
关键词
-
资金
- NIDDK NIH HHS [P30 DK 27651] Funding Source: Medline
Cystic fibrosis lung disease is characterized by a self-propagating cycle of obstruction, infection, and inflammation. The inflammatory response, which accounts for the majority of the morbidity and mortality of the disease, begins early in life, becomes persistent, and is excessive relative to the bacterial burden. Therapies aimed at decreasing the inflammatory response represent a relatively new strategy for treatment. This article reviews the current state of the art of anti-inflammatory therapy in cystic fibrosis and introduces clinical trials that are underway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据